Intervention Review

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

  1. Katherine Deane2,
  2. Sybille Spieker3,
  3. Carl E Clarke1,*

Editorial Group: Cochrane Movement Disorders Group

Published Online: 18 OCT 2004

Assessed as up-to-date: 6 JUN 2004

DOI: 10.1002/14651858.CD004554.pub2


How to Cite

Deane K, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004554. DOI: 10.1002/14651858.CD004554.pub2.

Author Information

  1. 1

    City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Department of Neurology, Birmingham, West Midlands, UK

  2. 2

    Newcastle University, Institute of Health & Society, Newcastle-upon-Tyne, UK

  3. 3

    Marburg, Germany

*Carl E Clarke, Department of Neurology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Dudley Road, Birmingham, West Midlands, B18 7QH, UK. c.e.clarke@bham.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 OCT 2004

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andrew J. Lees, Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease, CNS Neuroscience & Therapeutics, 2008, 14, 1, 83

    CrossRef

  2. 2
    Andrew J. Lees, Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease, CNS Neuroscience & Therapeutics, 2008, 14, 1